{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 134,
  "pageCount": 197,
  "prevPage": 133,
  "nextPage": 135,
  "slideType": "preempt_rebuttal",
  "function": "expose_gap",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a process-flow style layout to show the progression from generic challenges to specific settlement outcomes.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "logo_grid",
    "process_diagram",
    "screenshot"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/134",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-134",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "As one of the world’s best-selling drugs, REVLIMID faces significant pressure from generic challengers, pressure that we believe will continue to increase as REVLIMID nears full genericization in 2026",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f19-73dd-8e9e-8ea35d3ad62e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.4,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "image",
      "text": "List of generic companies: Mylan, Dr. Reddy's, Teva, Zydus, Hetero, Apotex, Sun Pharma, Cipla, Natco",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97483c6d-ebd1-45ef-a82d-d5a8feb6cb0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "list",
      "text": "Settlement details for Natco (2022/2026) and Accord (2022), plus Alvogen launch in 2019.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "445f4e0f-dc1d-4b69-8c89-10aebe8001a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Celgene is currently engaged in litigation with nine generic manufacturers over its REVLIMID patents, and has already settled with two. It is reasonable to believe additional generic challengers will emerge.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "988fadc4-8b52-4e3e-a2ef-9a839713a0ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "As one of the world's best-selling drugs, REVLIMID faces significant pressure from generic challengers, pressure that we believe will continue to increase as REVLIMID nears full genericization in 2026",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c68b09f9-b363-4090-8583-d09ecec98b4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Just as it’s enjoying a reprieve in the U.S., Celgene’s Revlimid gets generic rival in Europe — FiercePharma",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0f19-73dd-8e9e-91758dec0bdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Public company filings, news reports.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb000d3b-c263-4637-ad01-b41e56ae4ed9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "REVLIMID Fully Genericizes Earlier Than 2026",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59df9dbc-3e31-4715-9b7f-80cda88d78da",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}